SCHEDULE: Fresenius Ownership in Humacyte Dips to 8.4%
Beneficial Ownership Amendment
Fresenius Medical Care's beneficial ownership in Humacyte, Inc. decreased to 8.4% due to share dilution, not share sales.
Summary
- Fresenius Medical Care Holdings, Inc. (FMCH) and Fresenius Medical Care AG (FME AG) reported a beneficial ownership of 18,312,735 shares of Humacyte, Inc. Common Stock.
- This represents approximately 8.4% of Humacyte's outstanding voting shares.
- The percentage ownership decreased from 9.5% (reported in Amendment No. 6) to 8.4% solely due to an increase in Humacyte's total outstanding shares.
- Humacyte's outstanding shares increased to 218,453,511 as of March 20, 2026, primarily from a 25,000,000 share issuance on that date.
- Neither FMCH nor FME AG has acquired or disposed of any Humacyte shares since their initial Schedule 13D filing in September 2021.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a slightly negative development for existing shareholders due to dilution, although it reflects Humacyte's capital raising activities which may be necessary for its operations and growth.
Negatives
- Existing shareholders, including Fresenius, experienced dilution as the percentage of ownership decreased from 9.5% to 8.4% due to new share issuances by Humacyte.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Humacyte's future performance or Fresenius's investment strategy beyond the current ownership disclosure.
Industry Context
StockSavvy.ai notes that a decrease in percentage ownership due to share dilution, without the reporting entity selling shares, is a common occurrence for companies that raise capital through equity issuances. This indicates Humacyte has likely undertaken recent financing activities, which can be typical for biotechnology or medical device companies requiring significant capital for R&D or commercialization.
Stakeholder Impact
- Shareholders: Experience dilution of their ownership percentage due to the issuance of new shares by Humacyte.
Key Dates
| Date | Description |
|---|---|
| 2021-09-02 | Initial Schedule 13D filed by Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG. |
| 2023-12-01 | Amendment No. 1 to Schedule 13D filed. |
| 2024-03-07 | Amendment No. 2 to Schedule 13D filed. |
| 2024-11-18 | Amendment No. 3 to Schedule 13D filed. |
| 2025-05-22 | Amendment No. 4 to Schedule 13D filed. |
| 2025-10-16 | Amendment No. 5 to Schedule 13D filed solely by FME AG. |
| 2025-11-12 | Humacyte's Form 10-Q filed, showing 187,727,321 shares outstanding. |
| 2025-12-15 | Humacyte issued 5,725,190 shares, as reported in its Form 8-K. |
| 2026-01-09 | Amendment No. 6 to Schedule 13D filed by FME AG and FMCH. |
| 2026-03-19 | Humacyte reported issuance of 25,000,000 shares in its Form 8-K. |
| 2026-03-20 | Date of event requiring filing of this statement; 25,000,000 shares issued by Humacyte, bringing total outstanding to 218,453,511. |
| 2026-03-24 | Date of signing for Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG for Amendment No. 7. |
Recommendation
holdThe filing primarily reports a change in percentage ownership due to dilution from Humacyte's share issuances, not a change in Fresenius's investment thesis or a sale of shares. While dilution is generally negative, Fresenius maintains a substantial stake, suggesting continued strategic interest. A 'hold' recommendation is appropriate as the filing does not provide new information on Humacyte's operational performance or future prospects that would warrant a change in investment strategy, but rather confirms recent capital raising activities.
Keywords
Humacyte, Fresenius Medical Care, Schedule 13D, Beneficial Ownership, Share Dilution, Common Stock, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.